Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 676 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morning Group Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 20, 2026, 5:26 AM EDT
Withdrawn Early Phase 1 Interventional

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288
View directory record Official record
Conditions
COVID-19
Interventions
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

NCT03749746
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertension, Obesity, Overweight and Obesity, Pregnancy Complications, Pregnancy Toxemia, Postpartum Preeclampsia
Interventions
Home Blood Pressure Monitoring, Heart Health 4 New Moms, Usual care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Adjunctive Bright Light Therapy for Opioid Use Disorder

NCT05459922
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Wearable bright light therapy device, Wearable placebo light therapy device
Device
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Strawberry Consumption on the Microbiome

NCT04217122
View directory record Official record
Conditions
Microbiome
Interventions
strawberry powder, placebo powder
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 20, 2026, 5:26 AM EDT
Withdrawn Not applicable Interventional

Benefits of Nutritional Ingredients for Type 2 Diabetes

NCT06327711
View directory record Official record
Conditions
Diabetes type2
Interventions
Control: CHO Blend, Experimental: CHO Blend plus AN100
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
View directory record Official record
Conditions
Phenylketonuria
Interventions
Kuvan, Diet
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
4 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
View directory record Official record
Conditions
Asthma
Interventions
FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Terminated Phase 3 Interventional Results available

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

NCT02936037
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MD1003 100mg capsule, PLACEBO
Drug
Lead sponsor
MedDay Pharmaceuticals SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

NCT04634071
View directory record Official record
Conditions
Smoking Cessation, Cancer, Treatment-Related
Interventions
Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products
Drug · Behavioral · Other
Lead sponsor
Joseph Valentino, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Concussion Treatment in Older Adults

NCT05849064
View directory record Official record
Conditions
Concussion, Mild
Interventions
Behavioral Control, Targeted Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

NCT02482298
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

The Back Pain Consortium Research Program Study

NCT04870957
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
PainGuide, MBSR, PT and exercise, Self -administered acupressure, Duloxetine, Pro-Diary monitor
Behavioral · Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 70 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Phase 1 Interventional

Beta-blocker Administration for Cardiomyocyte Division

NCT04713657
View directory record Official record
Conditions
Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions
N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection
Other · Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Days to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Cabenuva Injection Tracking in CHORUS

NCT04863261
View directory record Official record
Conditions
HIV Infections
Interventions
Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
Other
Lead sponsor
Epividian
Industry
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327
View directory record Official record
Conditions
Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Interventions
Ocufolin
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NCT05011305
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Fibrosis
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
101
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 5:26 AM EDT
Withdrawn Phase 2 Interventional

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

NCT06473974
View directory record Official record
Conditions
Facial Hyperpigmentation
Interventions
Test cosmetic product
Drug
Lead sponsor
Kayuraeffect, LLP
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 20, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

NCT05912621
View directory record Official record
Conditions
Obesity, Overweight and Obesity, Overweight
Interventions
Tirzepatide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Hypnosis Therapy on Outcomes in Shoulder Replacement Therapy

NCT04889833
View directory record Official record
Conditions
Anxiety, Opioid Use
Interventions
hypnosis therapy
Behavioral
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 20, 2026, 5:26 AM EDT